Sera Prognostics (NASDAQ:SERA) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Sera Prognostics (NASDAQ:SERA) has received a "Sell (D-)" rating from Weiss Ratings, reflecting ongoing bearish sentiment towards the stock.
• The company's recent earnings report showed a loss of ($0.16) earnings per share, slightly better than the consensus estimate of ($0.21), but revenues fell short of expectations.
• Insider activity included CEO Zhenya Lindgardt selling 21,158 shares at $3.15, decreasing his ownership by 2.54% amid a broader trend of insider sales at the company.

Sera Prognostics (NASDAQ:SERA - Get Free Report)'s stock had its "sell (d-)" rating reissued by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of "Sell".

Sera Prognostics Price Performance

SERA opened at $3.15 on Wednesday. The firm has a fifty day moving average price of $2.90 and a 200 day moving average price of $2.74. Sera Prognostics has a 1 year low of $1.37 and a 1 year high of $9.13. The stock has a market cap of $118.67 million, a P/E ratio of -3.71 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. The firm had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Equities analysts expect that Sera Prognostics will post -0.96 EPS for the current year.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 21,158 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $66,647.70. Following the completion of the sale, the chief executive officer directly owned 811,136 shares in the company, valued at $2,555,078.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 50,631 shares of company stock valued at $153,604 in the last ninety days. 13.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds have recently modified their holdings of SERA. Aberdeen Group plc acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $4,563,000. AWM Investment Company Inc. raised its position in shares of Sera Prognostics by 48.1% in the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock valued at $3,190,000 after buying an additional 281,703 shares during the last quarter. Sanders Morris Harris LLC raised its position in shares of Sera Prognostics by 179.8% in the second quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company's stock valued at $730,000 after buying an additional 169,400 shares during the last quarter. Perkins Capital Management Inc. acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $522,000. Finally, Captrust Financial Advisors raised its position in shares of Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock valued at $1,668,000 after buying an additional 100,366 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.